Northland analyst Carl Byrnes downgraded Oncternal Therapeutics to Market Perform from Outperform with a price target of $2, down from $25, after the company announced its decision to discontinue its clinical trials evaluating ONCT-534, its dual action androgen receptor inhibitor for the treatment of patients with metastatic castration resistant cancer, and ONCT-808, its ROR1-targeting autologous CAR T program for the treatment of patients with aggressive B-cell lymphoma, and to explore strategic alternatives
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ONCT:
- Oncternal Therapeutics downgraded to Hold from Buy at Brookline
- Oncternal Therapeutics trading resumes
- Oncternal Therapeutics Announces Termination of its Clinical Studies and Exploration of Strategic Alternatives
- Oncternal terminates ONCT-534, ONCT-808 studies, explores strategic alternatives
- Oncternal Therapeutics trading halted, news pending